Optimizerx Corp Stock Price, News & Analysis

OptimizeRx Corp. (Nasdaq: OPRX) has announced internal management changes aimed at strengthening its operational and financial strategy. CEO Will Febbo highlighted a 45% compounded annual growth rate over the past three years and a market cap nearing $1 billion. Ed Stelmakh has joined as CFO and COO, focusing on key performance indicators and scaling operations. Miriam Paramore will transition to an advisory role, having successfully transitioned her responsibilities. The leadership team aims to leverage technology for improved patient health outcomes in the growing digital healthcare market.

OptimizeRx Corp (Nasdaq: OPRX) announced a remarkable 257% revenue growth, attributed to brand acquisition and product adoption, during the recent Deloitte Technology Fast 500 ranking announcement.

CEO William Febbo expressed confidence in the company’s growth trajectory, emphasizing their position in the digital point-of-care sector. The Deloitte award is a recognition of the top 500 fastest-growing tech companies in North America, showcasing OptimizeRx's robust performance from 2017 to 2020.

OptimizeRx Corp (Nasdaq: OPRX) announced its participation in the Piper Sandler 33rd Annual Virtual Healthcare Conference, taking place from November 22 to December 2, 2021. The management team will engage in presentations available to registered attendees and hold 1x1 meetings through the conference platform. OptimizeRx is known for its point-of-care technology solutions aimed at improving patient engagement and therapy adherence, reaching over 60% of U.S. healthcare providers through its therapy initiation system.

OptimizeRx Corp. (Nasdaq: OPRX) is hosting its second annual Innovate4Outcomes event on December 9, 2021, from 1:00 PM to 4:30 PM ET. This virtual workshop aims to address patient access and support challenges in U.S. healthcare, bringing together pharmaceutical executives, healthcare providers, and advocacy leaders. The event will feature collaborative sessions to develop actionable solutions for systemic healthcare challenges. Notable advocacy groups like I AM ALS and RESOLVE will participate, showcasing their experiences to shape better patient outcomes.

OptimizeRx Corp. (Nasdaq: OPRX) reported a 53% revenue increase to $16.1 million for Q3 2021, compared to $10.5 million in Q3 2020. Year-to-date revenue rose 52% to a record $41.0 million. Gross profit grew 51% to $9.1 million, though gross profit margin slightly decreased to 56.3%. The company achieved a non-GAAP net income of $1.6 million, or $0.09 per share. Cash and equivalents increased to $85.0 million. The number of brands utilizing its solutions rose to 182 from 140 in the previous quarter.

OptimizeRx Corp (Nasdaq: OPRX) released an analysis highlighting the barriers to therapy initiation and persistence for multiple sclerosis (MS) patients. The research underscores the significance of early treatment, which can slow disease progression and mitigate new brain damage. Challenges such as misdiagnosis and high costs hinder timely treatment. The analysis suggests that leveraging real-world data and AI-driven solutions could enhance diagnosis and support for patients, ultimately improving adherence to therapy. The median annual cost of branded disease-modifying therapies exceeds $90,000, creating financial barriers.

OptimizeRx Corp. (Nasdaq: OPRX) will hold a conference call on November 9, 2021, at 4:30 p.m. ET to discuss its third-quarter financial results for the period ending September 30, 2021. The call will include a Q&A session and will be available via webcast. OptimizeRx offers digital health solutions connecting healthcare providers and patients, with a focus on therapy initiation and adherence programs. The company emphasizes its AI-driven marketing efforts to enhance patient engagement and treatment adherence.